Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe.

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Sitosterolemia is a rare genetic disorder characterized by the accumulation of plant sterols.
• Thyroid hormone status can be influenced by various metabolic factors.
• Ezetimibe (EZE) is a cholesterol absorption inhibitor with potential effects on sterol metabolism.

Purpose of the Study:

• To investigate the relationship between thyroid status biomarkers and 5α-stanols in patients with sitosterolemia.
• To evaluate the impact of ezetimibe (EZE) treatment on these biomarkers.

Main Methods:

• A study involving eight patients with sitosterolemia over 28 weeks (14 weeks off EZE, 14 weeks on EZE 10 mg/day).
• Measurement of serum thyroid biomarkers (FT3, FT4, FT3/FT4 ratio, TSH) and 5α-stanols (sitostanol, cholestanol).
• Assessment of cholestanol precursors including total cholesterol and lathosterol.

Main Results:

• Ezetimibe (EZE) significantly reduced plasma and red blood cell levels of sitostanol and cholestanol.
• EZE treatment led to a significant increase in the free triiodothyronine to free thyroxine ratio (FT3/FT4).
• The reduction in plasma cholestanol inversely correlated with the increase in FT3/FT4.

Conclusions:

• 5α-stanols levels in sitosterolemia patients may be linked to thyroid function.
• Ezetimibe (EZE) reduces circulating 5α-stanols and enhances the FT3/FT4 ratio.
• These findings suggest EZE may improve thyroid hormone status by increasing T4 to T3 conversion.